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Abstract
Background: The diameter of balloons or stents is selected according to the esti-
mated reference vessel diameter and do not adapt to the vessel anatomy. The aim of
the present preclinical studies was to investigate a novel, vessel anatomy adjusting
hypercompliant drug-coated balloon catheter (HCDCB).
Methods: Hypercompliant balloon membranes were coated in a constricted state with
high drug density. Drug adherence was investigated in vitro, transfer to the porcine
peripheral arteries and longitudinal distribution in vivo. In young domestic swine,
neointimal proliferation was induced by vessel overstretch and continuous irritation by
permanent stents. Uncoated hypercompliant balloons (HCB), and standard uncoated
balloons and drug-coated balloons (DCB) served as controls. Efficacy was assessed by
angiography, optical coherence tomography (OCT), and histomorphometry.
Results: HCDCB lost 18.0 ± 3.9% of dose during in vitro simulated delivery to the
lesion. Drug transfer to the vessel wall was 13.9 ± 6.4% and drug concentration was
1,044 ± 529 ng/mg tissue. Four weeks after treatment, the histomorphometric
neointimal area was smaller with HCDCB versus uncoated HCB (2.39 ± 0.55 mm2
vs. 3.26 ± 0.72 mm2, p = .038) and area stenosis (OCT) was less (11.6 ± 6.9%
vs. 24.7 ± 9.7%, p = .022). No premature death occurred and no in-life clinical symp-
toms or treatment-associated thrombi were observed.
Conclusions: HCDCB were found to inhibit excessive neointimal proliferation. Bal-
loon adaption to different vessel diameters and shapes may provide drug-delivery in
irregular lumen and facilitate balloon selection.
K E YWORD S
drug transfer, inhibition of neointimal proliferation, vessel anatomy adjusting drug-coated
balloon
1 | INTRODUCTION
Restenosis after percutaneous transluminal procedures occurs due to
the vessel wall trauma induced by balloon dilatation or stent
Abbreviations: DCB, drug-coated balloon (=standard drug-coated PTA balloon); FU, follow-
up; HCB, hypercompliant balloon; HCDCB, hypercompliant drug-coated balloon; MLD,
minimal lumen diameter; OCT, optical coherence tomography; PTA, percutaneous
transluminal angioplasty; QA, quantitative angiography; RFD, reference diameter; SLD, stent
struts-to-lumen distance.
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deployment in several vascular territories.1 Drug-eluting stents (DES)
and drug-coated balloons (DCB) reduce restenosis by inhibition of
neointimal growth by local delivery of antiproliferative drugs. Further-
more, lumen enlargement after angioplasty alone may be induced by
paclitaxel-coated balloon catheters.2 Currently used noncompliant
and semi-compliant balloons are inflated to a predetermined cylindri-
cal shape and as a consequence do not adjust to the natural anatomy
of the vessel. To accomplish the required vessel wall contact, the
diameter of the cylinder has to be carefully chosen in advance
according to the desired or achieved lumen diameter of the treated
segment. DCB with too small diameter lack vessel wall contact and
thus do not provide sufficient drug transfer, and those with too large
diameters cause undesired vessel injury. During dilatation of the main
artery of bifurcation lesions with currently available DCB, carina shift
into side branches may be adversely affected, and may thus not be
reached by the DCB surface. Whereas self-expanding stents adjust
within certain limits to the vessel diameter, current DCB do not. Long
vessel segments with variable diameters require treatment with more
than one DCB with different diameters. The novel concept of a
hypercompliant drug-coated balloon (HCDCB) allows for adjustment
to a wide range of diameters and irregularities of the vessel shape at
low inflation pressure and with no mechanical harm to narrow seg-
ments. For treatment of a given vessel territory, the only variable in
selecting a suitable HCDCB remains a sufficient balloon length. There-
fore, the aim of the present preclinical studies was to investigate a
novel, vessel anatomy adjusting paclitaxel-coated balloon catheter.
2 | MATERIAL AND METHODS
2.1 | Balloon catheters and stents
2.1.1 | Hypercompliant drug-coated balloons
Hypercompliant balloons, made of a stretchable biocompatible elas-
tomer, were coated with 60 μg paclitaxel/mm of balloon length
(2.7 μg/mm2 of 7 mm vessel diameter) in a proven matrix.3 Catheters
used for the experiments were equipped with 50 or 200 mm bal-
loons, were 0.03500 guidewire compatible, over-the-wire, and sterile.
To protect coating during the passage of the hemostatic valve of
introducers, a 7F peel-away introducer (Adelante, Oscor, Palm Har-
bor, FL) was used. Maximum usable diameter of inflated balloons
was 12 mm.
2.1.2 | Control balloon catheters
Uncoated hypercompliant and standard percutaneous transluminal
angioplasty (PTA) balloon catheters, either uncoated (Admiral Xtreme,
Medtronic, Minneapolis, MN) or coated with paclitaxel (In.PACT
Admiral, Medtronic), 4.0 × 40 mm length, were used as controls.
2.1.3 | Stents
To promote neointimal proliferation in the efficacy study,
Express Vascular SD balloon-expandable stents (4.0 × 19 mm,
Boston Scientific, Maple Grove, MN) were implanted in the
internal iliac arterial segments to be treated with either
balloon.
2.2 | Drug adherence and release
Adherence and loss of the drug coating was tested during in vitro sim-
ulated passage of the balloon to the lesion. HCDCB were passed
through a blood-filled 7 French guiding sheath (Terumo Destination,
65 cm in length, Terumo Europe, Leuven, Belgium). The balloons were
advanced in a vial with stirred heparinized porcine blood at 37C, kept
in blood for 1 min, placed in an empty vial, inflated, and cut off from
the catheter shaft.
2.3 | Animal experiments
Animal experiments were conducted in a total of 30 arteries in
15 domestic pigs weighing 21.0–31.0 kg. All applicable institu-
tional and/or national guidelines for the care and use of animals
were followed, for example, EU Commission Directive 86/609/
EEC and German Animal Protection Act (IMTR 42502-2-1378
and 42502-2-1405, Sachsen-Anhalt, Germany). Before the
experimental interventions, animals were treated as described
previously.4
2.3.1 | Drug transfer and longitudinal drug
distribution study
A short marker stent was implanted distal to the end of the segment
selected for treatment. HCDCB (200 mm long) were advanced to
external iliac and femoral arteries. Under fluoroscopy, the balloons
were inflated in their full length with conspicuous formation of pro-
trusions at vessel branches. The duration of each inflation was
120 s. About 20 min after treatment of the last artery, animals were
euthanized. Vessel segments were in situ labeled and ligated at
defined positions of the treated vessel using surgical thread
(Figure 1). Major side branches were closed. The length of each
ligated vessel segment was measured or determined on angiograms
using the ImageJ program (https://imagej.nih.gov/ij/). Following dis-
section of the whole treated artery including adjacent segments of
major side branches the side branches were cutoff from the main
vessel, which was then cut at the labeled positions to obtain seg-
ments with different diameters. All vessel samples were weighed
and kept at −20C for drug analysis.
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2.3.2 | Efficacy and tolerance study
The study investigating inhibition of neointimal proliferation by
HCDCB and tolerance was performed in 12 pigs; the study design is
depicted in Figure 2. Starting 2 days before treatment, 75 mg
clopidogrel and 100 mg acetylsalicylic acid daily were administered
and continued until sacrifice. Solely to enhance neointimal prolifera-
tion, balloon expandable bare metal were implanted in right and left
internal iliac arteries applying inflation pressures to achieve ~20%
overstretch of the vessel diameter. Uncoated HCB or HCDCB (balloon
length 50 mm) were introduced into the stented vessel segment as
described above. The balloons were placed in the stented vessel seg-
ment and were inflated under fluoroscopy by applying minimal pres-
sure allowing full-length expansion. For uncoated and drug-coated
PTA balloons, the same procedure as described above was applied
except that no peel-away introducer was used. To guarantee suffi-
cient contact with the vessel wall, the balloons were inflated applying
2 atm higher inflation pressure than used for stent implantation. For
all balloons, the duration of each inflation was 120 s. After deflation,
the balloons were retracted and kept in tubes for analysis of residual
paclitaxel on balloons.
Following completion of all study interventions, the carotid
arteriotomy was sutured, and the dermal layers were closed using
standard techniques. During treatment and at 4-weeks follow-up, iliac
arteries were visualized with fluoroscopy using contrast agent
followed by OCT of internal iliac arteries. Thereafter, animals were
euthanized as described above. Treated vessel segments were dis-
sected and preserved in 4% formalin solution for histomorphometry.
2.4 | Optical coherence tomography
Optical coherence tomography (OCT) images were recorded using the
ILUMIEN™OPTIS™ system (St. Jude Medical GmbH, St. Paul, MN)
after stenting followed by balloon treatment (post treatment), and at
follow-up. A Dragonfly™ OPTIS™ imaging catheter (St. Jude Medical
GmbH) was advanced to the target vessel segment. Images of the
internal iliac arterial segment to be investigated were acquired. Quali-
tative and quantitative analyses were done on the ILUMIEN™OPTIS™
offline review workstation (St. Jude Medical), and cross-sectional
parameters were measured after calibration.
2.5 | Quantitative analysis of radiographs (QA)
The CAAS II system (Pie Medical, Maastricht, the Netherlands) was
used for quantitative analysis of angiograms by an experienced
observer blinded to treatment groups.
2.6 | Histomorphometry
Stented artery segments were prepared for histomorphometry as
described in Reference 5, except that the “NIS BR 3.0” image program
was used for histomorphometric measurements as described in Refer-
ence 6.
2.7 | Analysis of paclitaxel
Paclitaxel contents of unused and used coated balloons and treated
vessel segments were determined by high-performance liquid chro-
matography (HPLC) with ultraviolet (UV) detection as described in
Reference 5.
2.8 | Statistical analysis
Quantitative angiographic, OCT, and histomorphometric parameters
obtained with the different balloon types were compared in a pairwise
fashion by unpaired Student's t test. A value of p < .05 was considered
statistically significant. Data are presented as mean ± SD.
F IGURE 1 Segments of a porcine external iliac/femoral artery for
determination of longitudinal drug distribution after inflation of a long
hypercompliant drug-coated balloon catheter (HCDCB). Porcine
external iliac/femoral artery with segments A–D of the main vessel
and side branches as dissected for measurement of drug content after
treatment of the artery with a 200 mm HCDCB. Vessel segments A–
D (sections marked with white lines) were obtained after cutting at
the ligated positions. Side branches were ligated at the orifice and
cutoff from the main vessel (sections marked with white or black
dotted lines). A stent (white box) was placed distal to segment D to
unequivocally label the adjacent but non-balloon-treated distal
segment of the vessel
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3 | RESULTS
3.1 | Properties of the device
HCDCB differ from DCB in the characteristics listed in Table 1. HCB
accommodate a wide range of vessel diameters at low inflation pres-
sure and adjust to the endoluminal surface of the artery with circum-
ferential apposition (Figure 3b). By contrast, PTA balloons adjust the
vessel lumen and vessel diameter to the predetermined cylindrical
shape upon application of high inflation pressure (Figure 3c,d).
3.2 | Drug adherence, release, and transfer to the
vessel wall using HCDCB
Advancement of the balloon to the lesion was simulated in vitro by
introduction of HCDCB through a membrane valve of a blood-filled
Terumo Destination 7F guiding sheath via a 7F introducer and contact
of the balloon with stirring blood. Loss of paclitaxel was 18.0 ± 3.9%
of dose, n = 4.
In a subsequent study, the transfer of the drug to the vessel wall
and its longitudinal distribution were investigated in porcine external
iliac/femoral arteries. HCDCB, 200 mm long to cover large and nar-
row diameter segments with the same balloon, were inflated in six
external iliac/femoral arteries applying a mean pressure of 0.7
± 0.4 atm. The mean length of the external iliac/femoral segments
treated with HCDCB was 194 ± 4 mm (Table 2). Mean vessel diame-
ter decreased from 5.5 ± 0.1 mm (proximal external iliac artery) to
F IGURE 2 Design of the study investigating efficacy and tolerance of hypercompliant drug-coated balloon catheter (HCDCB) in porcine
internal iliac arteries. OCT, optical coherence tomography; PTA, percutaneous transluminal angioplasty
TABLE 1 Differences in physical characteristics of
hypercompliant drug-coated balloons (HCDCB) and drug-coated
percutaneous transluminal angioplasty (PTA) balloons (DCB)
HCDCB DCB
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2.9 ± 0.3 mm (distal femoral artery). Drug analysis by vessel segment
(A–D, see Figure 1) revealed the highest proportion and amount of pacli-
taxel in segment C, which extended from the origin of the lateral femoral
circumflex artery to that of the saphenous artery (4.4 ± 1.8% of drug on
the balloon or 517 ± 214 μg), and the lowest proportion in tissue of the
short segment B (1.6 ± 0.7% or 188 ± 77 μg), which extended between
the side branches of the profunda femoris and lateral femoral circumflex
arteries. The mean sum of paclitaxel proportions in all vessel segments
was 1,622 ± 744 μg, corresponding to 13.9 ± 6.4% of dose on the bal-
loons; the mean concentration was 1,044 ± 529 ng/mg tissue. Paclitaxel
content in each vessel segment varied with the length of the dissected
vessel segment. Paclitaxel content calculated in relation to the surface
area of the corresponding vessel segment was depending on vessel
diameter (drug in segment A with a vessel diameter of 5.5 ± 0.1 mm:
0.39 ± 0.24 μg/mm2 of vessel surface area vs. segment D with a vessel
diameter of 2.9 ± 0.3 mm: 1.2 ± 1.1 μg/mm2 of vessel surface area). A
small amount of paclitaxel was also found in the short segments of side
branches (38 ± 36 μg or 133 ± 127 ng/mg tissue).
3.3 | Efficacy and tolerance study
To stimulate neointimal proliferation stents were implanted in internal
iliac arteries of 12 pigs applying significant vessel overstretch. Immedi-
ately afterwards, the stented vessel segments were treated with either
uncoated or coated hypercompliant or Admiral PTA balloons (i.e., four
balloon groups à six arteries; for study design, see Figure 2). No device
failures were observed. Hypercompliant or PTA balloons were inflated at
pressure less than 1.5 atm or at 10 atm, respectively.
3.4 | Inhibition of neointimal proliferation
3.4.1 | General
Luminal narrowing due to neointimal proliferation was assessed by
angiography, OCT, and histomorphometry (Tables 3–5). Baseline ves-
sel measures did not differ between treatment groups.
F IGURE 3 Inflation of hypercompliant drug-coated balloon catheter (HCDCB) and percutaneous transluminal angioplasty (PTA) balloons in a
porcine external iliac/femoral artery. (a) External iliac/femoral artery before balloon insertion and inflation; (b) hypercompliant balloon (100 mm,
full contact to the vessel wall) inflated at 0.7 atm; and (c and d) PTA balloon (4.0 × 100 mm in c: proximal balloon portion without contact to the
vessel wall; 5.0 × 100 mm in d: overstretch of the distal artery portion, both inflated at 6 atm, in an external iliac/femoral artery. Images were
taken from a separate experiment to illustrate the difference in vessel wall conformity

















in vivo inflation in
peripheral artery
[% of dose on balloon][μg] [ng/mg tissue]
[% of dose
on balloon]
A 6 59.5 ± 7.6 5.5 ± 0.1 416 ± 280 854 ± 569 3.56 ± 2.39 0.39 ± 0.24
B 6 26.7 ± 3.9 4.8 ± 0.3 188 ± 77 1,191 ± 555 1.60 ± 0.66 0.46 ± 0.15
C 6 64.5 ± 5.6 3.6 ± 0.4 517 ± 214 1811 ± 922 4.42 ± 1.83 0.69 ± 0.20
D 6 43.0 ± 5.9 2.9 ± 0.3 464 ± 476 1,307 ± 1,136 3.97 ± 4.07 1.16 ± 1.12
Side branchesb 6 37.8 ± 35.7 133 ± 127 0.32 ± 0.30
Vessel total 6 194 ± 5 1,622 ± 744 1,044 ± 529 13.9 ± 6.4 3.5 ± 4.8
aSegments A–D: see Figure 1.
bSum of paclitaxel found in all side branches (lateral iliac circumflex, profunda femoris, lateral femoral circumflex, and saphenous arteries, each up to
~5 mm distal of the main artery). Data presented as mean ± SD.
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TABLE 3 Quantitative angiography of in-stent vessel segment of internal iliac arteries at intervention and 4-week follow-up (efficacy and
tolerance study)
Hypercompliant balloon Standard PTA balloon p Values HCDCB* versus
Coated (HCDCB*) Uncoated (HCBI) Coated (DCBx) Uncoated (UBII) Uncoated (HCBI) Coated (DCBx)
n (analyzed vessels) 6 6 6 6
Quantitative angiography at stent implantation followed by balloon treatment
RFDa (mm) 2.12 ± 0.41 2.21 ± 0.26 2.32 ± 0.38 2.48 ± 0.46 0.645 0.403
Stent diameter (mm) 3.00 ± 0.54 2.92 ± 0.22 3.05 ± 0.41 3.40 ± 0.42 0.725 0.875
Overstretch ratio 1.42 ± 0.10 1.32 ± 0.05 1.32 ± 0.08 1.40 ± 0.24 0.054 0.081
At 4-week follow-up
RFD (mm) 2.47 ± 0.41 2.42 ± 0.20 2.35 ± 0.75 2.83 ± 0.12 0.798 0.767
MLDb in-stent (mm) 2.91 ± 0.57 2.52 ± 0.28 2.68 ± 0.68 2.72 ± 0.90 0.164 0.536
Reduction in MLD in-stent at FUc (mm) 0.16 ± 0.07 0.48 ± 0.37 0.47 ± 0.43 0.76 ± 0.87 0.071 0.112
SLDd (mm) 0.27 ± 0.29 0.75 ± 0.69 1.13 ± 0.71 1.12 ± 1.25 0.145 0.020
In-stent diameter (%) 118 ± 14 101 ± 14 112 ± 18 98 ± 28 0.083 0.608
*Drug-coated hypercompliant balloons; I(uncoated) hypercompliant balloons; xdrug-coated PTA balloons; IIuncoated PTA balloons.
aRFD, reference diameter.
bMLD, minimal lumen diameter.
cFU, follow-up; overstretch ratio: stent diameter/reference vessel diameter; reduction in MLD in-stent at FU = MLD stent-MLD lumen FU, SLD.
dStent struts-to-lumen distance = maximal distance between stent struts and lumen; in-stent diameter (% of RFD) = values larger than 100 indicate
persistent oversize of lumen versus RFD. Data presented as mean ± SD.
TABLE 4 OCT analysis of in-stent vessel segment of internal iliac arteries at 4-week follow-up (efficacy and tolerance study)
Hypercompliant balloon Standard PTA balloon p Values HCDCB* versus
Coated (HCDCB*) Uncoated (HCB') Coated (DCBx) Uncoated (UBII) Uncoated (HCB') Coated (DCBx)
n (analyzed vessels) 6 6 6 6
Lumen area (mm2) 6.29 ± 2.65 4.19 ± 0.83 5.52 ± 1.33 5.20 ± 4.53 0.093 0.540
Stent area (mm2) 7.07 ± 2.74 5.55 ± 0.71 6.64 ± 1.03 7.29 ± 3.84 0.210 0.734
Neointimal area (mm2) 0.78 ± 0.42 1.37 ± 0.55 1.12 ± 0.39 2.09 ± 1.44 0.065 0.179
Area stenosis (%) 11.6 ± 6.9 24.7 ± 9.7 17.1 ± 6.0 35.2 ± 28.7 0.022 0.172
Neointimal thickness (mm) 0.09 ± 0.05 0.18 ± 0.08 0.12 ± 0.04 0.23 ± 0.18 0.031 0.203
Note: Neointimal area = difference between inner stent area and luminal area; area stenosis (%) = [1−(lumen area/vessel area)] × 100; neointimal
thickness = distance from inner surface of stent struts to the luminal border. Data presented as mean ± SD.
*Drug-coated hypercompliant balloons; ' (uncoated) hypercompliant balloons; xdrug-coated PTA balloons; IIuncoated PTA balloons.
TABLE 5 Histomorphometrical analysis of in-stent vessel segment of internal iliac arteries at 4-week follow-up (efficacy and tolerance study)
Hypercompliant balloon Standard PTA balloon p Values HCDCB* versus
Coated (HCDCB*) Uncoated (HCB') Coated (DCBx) Uncoated (UBII) Uncoated (HCB') Coated (DCBx)
n (analyzed vessels) 6 6 6 6
Vessel diameter (mm) 3.25 ± 0.56 3.10 ± 0.29 3.38 ± 0.37 3.52 ± 0.60 0.591 0.644
Injury score (−) 1.08 ± 0.00 1.02 ± 0.64 1.41 ± 0.55 1.66 ± 0.82 0.878 0.439
Lumen diameter (mm) 2.73 ± 0.57 2.34 ± 0.30 2.69 ± 0.39 2.53 ± 0.94 0.170 0.891
Maximal neointimal thickness (mm) 0.32 ± 0.07 0.47 ± 0.08 0.51 ± 0.08 0.78 ± 0.64 0.0045 0.001
Luminal area (mm2) 6.13 ± 2.68 4.40 ± 1.06 5.97 ± 1.46 5.61 ± 4.22 0.173 0.898
Neointimal area (mm2) 2.39 ± 0.55 3.26 ± 0.72 3.21 ± 0.76 4.57 ± 2.32 0.038 0.057
Diameter stenosis (%) 16.4 ± 3.5 24.7 ± 4.7 20.9 ± 5.5 28.9 ± 17.7 0.006 0.121
Area stenosis (%) 29.3 ± 5.8 42.8 ± 7.6 35.8 ± 7.2 47.2 ± 22.3 0.006 0.115
Inflammation score (−) 2.48 ± 0.63 1.57 ± 0.84 2.34 ± 0.38 2.24 ± 0.61 0.058 0.642
Note: Values are mean ± SD (n = 6). *Drug-coated hypercompliant balloons; ' (uncoated) hypercompliant balloons; xdrug-coated PTA balloons, IIuncoated
PTA balloons.
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3.4.2 | Effect of HCDCB on neointimal
proliferation and comparison to uncoated HCB
At 4-week follow-up, OCT parameters area stenosis and neointimal thick-
ness, were significantly reduced in internal iliac arteries treated with
HCDCB compared to uncoated HCB (area stenosis 11.6 ± 6.9% vs. 24.7
± 9.7%, p = .022; neointimal thickness: 0.09 ± 0.05 mm vs. 0.18
± 0.08 mm, p = .031; Table 4; OCT images in Figure 4a,b). There was also
a tendency toward smaller neointimal area with HCDCB versus uncoated
HCB (0.78 ± 0.42 mm2 vs. 1.37 ± 0.55 mm2, p = .065). Histomorphometry
demonstrated significant inhibition of neointimal proliferation in internal
iliac arteries treated with HCDCB versus uncoated HCB (maximal
neointimal thickness: 0.32 ± 0.07 mm vs. 0.47 ± 0.08 mm, p = .0045;
neointimal area: 2.39 ± 0.55 mm2 vs. 3.26 ± 0.72 mm2, p = .038; diameter
stenosis: 16.4 ± 3.5% vs. 24.7 ± 4.7%, p = .006; area stenosis 29.3 ± 5.8%
vs. 42.8 ± 7.6%, p = .006; Table 5; histomorphometrical images in
Figure 4d,e), confirming the OCT findings. QA, however, showed no statis-
tically significant differences between the two balloon types, but a ten-
dency toward less neointima with HCDCB versus uncoated HCB (stent
struts-to-lumen distance [SLD]: 0.27 ± 0.29 mm vs. 0.75 ± 0.69 mm,
p = .145; reduction in in-stent minimal lumen diameter [MLD]: 0.16
± 0.07 mm vs. 0.48 ± 0.37 mm, p = .071; Table 3).
3.4.3 | Comparison of neointimal proliferation
after treatment with HCDCB and drug-coated PTA
balloons
The QA parameter SLD and histomorphometric parameter maximal
neointimal thickness were significantly lower with HCDCB versus drug-
coated PTA balloons (SLD: 0.27 ± 0.29 mm vs. 1.13 ± 0.71 mm,
p = .020; max. neointimal thickness: 0.32 ± 0.07 mm vs. 0.51 ± 0.08 mm,
p = .001, Tables 3 and 5). Most other QA and histomorphometric param-
eters indicated a tendency toward less neointima formation with
HCDCB versus drug-coated PTA balloons (reduction in in-stent MLD
[QA]: 0.16 ± 0.07 mm vs. 0.47 ± 0.43 mm, p = .112; neointimal area [his-
tomorphometry]: 2.39 ± 0.55 mm2 vs. 3.21 ± 0.76 mm2, p = .057; diam-
eter stenosis [histomorphometry]: 16.4 ± 3.5% vs. 20.9 ± 5.5%, p = .121;
area stenosis [histomorphometry]: 29.3 ± 5.8% vs. 35.8 ± 7.2%,
p = .115). In addition, OCT showed a trend toward smaller neointimal
area, stenosis area, and neointimal thickness, and hence less neointima
formation, in the HCDCB group versus drug-coated PTA balloon group
(neointimal area: 0.78 ± 0.42 mm2 vs. 1.12 ± 0.39 mm2, p = .179; area
stenosis: 11.6 ± 6.9% vs. 17.1 ± 6.0%, p = .172, Table 4).
3.4.4 | Injury and inflammation
No significant differences in injury and inflammation scores were
observed in overstretched and stented vessel segments, which were
subsequently treated with the different balloon types.
3.4.5 | Tolerance
All animals survived the interventional procedure without signs of
intolerance. Spasms observed shortly after treatment with either bal-
loon were minor and were without recognizable effect on 4-week
results. During the follow-up period, all animals gained weight and
showed no signs of pain or abnormal behaviors. No signs of
F IGURE 4 Porcine in-stent vessel segments treated with hypercompliant drug-coated balloon catheter (HCDCB) or percutaneous transluminal
angioplasty (PTA) balloons at 4-week follow-up. Optical coherence tomography (OCT) and histological images of the in-stent vessel segment in porcine
internal iliac arteries at 4-week follow-up. OCT (a–c) and histology (d–f) show neointimal formation in arteries treated with an uncoated HBC (a and d)
and suppression of neointimal proliferation in vessels treated with a HCDCB (b and e) or drug-coated PTA balloon (c and f)
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thrombotic or embolic events were noticed during or shortly after the
intervention or at reangiography 4 weeks later. Reangiography rev-
ealed no vascular abnormalities such as thrombotic occlusion or
aneurysms.
4 | DISCUSSION
Coronary angioplasty was introduced clinically by Andreas Grüntzig in
1977.7 Later on, stents were developed to cover flow-limiting dissec-
tions to prevent early vessel closure.8 It was shown that stents lead to
a reduction of restenosis compared to conventional angioplasty
(POBA).9 In the coronary arteries, DES became the therapy of choice
for interventional treatment of coronary artery disease10 due to favor-
able acute and subacute occlusion rates and low risk of restenosis of
new-generation DES. Meanwhile, DCB are accepted alternatives for
the treatment of coronary in-stent restenosis10 and under clinical
investigation for coronary de novo disease.11,12 In peripheral arterial
disease, DCB were about to become the standard therapy for the
transfemoral region.13
The basic principle of the balloon catheters used has remained
the same over the years. The balloons have a defined diameter, which
is usually reached at inflation with nominal pressure. Noncompliant
balloons almost do not change their diameter even at higher inflation
pressures, while semi-compliant balloons can still be stretched by
about 10% until the burst pressure is reached.14 The aim of the cur-
rent preclinical studies was to explore restenosis inhibition by a single
balloon construct that fits all vessel diameters within a certain vessel
territory, including treating the origins of side branches in the treated
main artery segment. This may be achieved by highly stretchable bal-
loon membranes that inflate at low pressure. In deflated state, these
membranes are not folded but contracted forming a tight tube around
the catheter shaft with the guidewire lumen. Challenges of this
approach are the coating procedure with the aim of a sufficient dose
on the small (contracted) surface, advancing the unprotected drug to
the lesion, and the drug delivery at a very low inflation pressure.
Encouraged by the findings on feasibility of drug delivery by DCB
at low inflation pressure (2 atm)6 and high conformability of hyper-
compliant balloons to vascular anatomy, we performed the preclinical
studies presented here to evaluate the HCDCB in terms of in vivo
drug deliverability. High-drug loading on contracted small surfaces of
stretchable balloon membranes and modest drug loss during passage
through hemostatic valves and introductory sheath prompted investi-
gations into inhibition of neointimal proliferation induced by prior
overstretch and stent implantation in porcine peripheral arteries. The
small surface of hypercompliant balloons in the non-inflated state was
coated with high drug density of 14 μg/mm2, corresponding to about
60 μg/mm of balloon length. The drug coating density on non-inflated
balloons was four times higher than on commercially available DCB
with maximum 3.5 μg paclitaxel/mm2. However, as the surface area
expands during inflation, drug density is reduced.
Loss of drug on the simulated way to the lesion was about 18%
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PTCA balloon catheter with a preliminary paclitaxel-urea-matrix coat-
ing formulation of about 26% of dose4 but somewhat higher than for
another standard DCB tested in a similar way.5 Despite balloon infla-
tion at low pressure (<1.5 atm), HCDCB delivered almost 14% of pac-
litaxel dose to the external iliac or femoral arteries after a single
inflation. This is a high proportion of the drug compared with the yield
achieved with drug-coated PTA balloons inflated with significantly
higher inflation pressure (Table 6). The porcine overstretch model
with simultaneous stent implantation to enhance neointimal prolifera-
tion15 has been extensively used for investigation of numerous coat-
ing variations for DCB catheters in coronary and peripheral
arteries.5,16,17 The study devices were compared with uncoated HCB
and Admiral PTA balloons. Furthermore, In.Pact Admiral PTA balloon
catheters were used as positive control.18 Four weeks after stenting
with subsequent balloon treatment, the degree of neointimal forma-
tion was evaluated by QA, OCT, and histomorphometry. Despite the
low inflation pressure applied in peripheral arteries, HCDCB were sim-
ilarly efficacious in inhibiting neointima formation as drug-coated PTA
balloons inflated at much higher pressure. QA showed less SLD and a
tendency toward less reduction of MLD after treatment with HCDCB
than after treatment with commercially available DCB. This finding
was confirmed by histomorphometry. A previous study in porcine cor-
onary arteries6 indicates that low-pressure drug delivery by drug-
coated PTA balloons is sufficient to reduce neointima proliferation. It
may support the use of HCDCB in treating diseased arteries after ves-
sel preparation in order to reach the entire arterial wall independently
of lumen diameter.
The results of the 4-week follow-up study presented here dem-
onstrate that treatment of peripheral arteries with HCDCB is toler-
ated in animal experiments as indicated by survival of all animals
without clinical symptoms and without treatment-associated acute or
subacute thrombi, vessel obstruction, or other abnormalities in the
final 4-week angiograms.
Endovascular treatment of femoropopliteal lesions is complicated
by the fact that the superficial femoral artery is one of the longest
vessels in the human body, reaching up to 30 cm in length. Vessel
preparation using, for example, PTA with uncoated balloons prior to
treatment with drug-coated PTA balloons is now an integral part of
restenosis prophylaxis. Expansion of the lumen unavoidably results in
arterial wall injury.19 Since common angioplasty balloons tend to
adjust the vessel lumen and vessel diameter to the predetermined
cylindrical shape at high inflation pressure, they may only be applied
to vessel segments with a fairly homogeneous diameter. This requires
the prior selection of balloons with an appropriate length and diame-
ter from a stock of a variety of devices with different dimensions, as
well as precise placement of balloons. We believe that HCDCB are
suitable for vascular treatment after vessel preparation. The clinical
field of application is primarily to be seen in the area of long diffusely
diseased vessels including the origins of side branches. Since the
HCDCB itself has hardly any dilating effect on the blood vessels,
lesion preparation is even more important than is the case with DCB
anyway. Especially calcified vascular areas require a very intensive
pretreatment, for example, by high-pressure PTA or scoring or cutting
balloons and/or debulking strategies such as atherectomy for luminal
gain, thrombectomy and plaque modification. This follows from the
balloon's long length and its ability to adapt to different vessel diame-
ters in order to guarantee close contact where the vessel diameter is
the largest while avoiding unnecessary distal luminal widening and
vessel injury.
5 | STUDY LIMITATIONS
The study was limited by its experimental nature. Although anti-
restenotic effects of clinically proven drug-coated PTA balloons were
shown in the animal model and our data indicate the safety of the
tested devices, our current findings cannot predict its clinical perfor-
mance in patients with peripheral arterial disease, especially in calci-
fied lesions, and sustainability cannot be evaluated in the existing
animal model, a known shortage of the model.20
6 | CONCLUSIONS
A novel, vessel anatomy adjusting paclitaxel-coated balloon catheter
has been investigated in preclinical models. This concept allows the
balloon membrane to be adapted to the natural anatomy of the vessel
and thus permits local drug application without additional vascular
trauma.
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